DK619186D0 - FUSION PROTEINS WITH EUKARYOTIC BALL STANDARD - Google Patents

FUSION PROTEINS WITH EUKARYOTIC BALL STANDARD

Info

Publication number
DK619186D0
DK619186D0 DK619186A DK619186A DK619186D0 DK 619186 D0 DK619186 D0 DK 619186D0 DK 619186 A DK619186 A DK 619186A DK 619186 A DK619186 A DK 619186A DK 619186 D0 DK619186 D0 DK 619186D0
Authority
DK
Denmark
Prior art keywords
fusion proteins
eukaryotic
ball standard
amino
ball
Prior art date
Application number
DK619186A
Other languages
Danish (da)
Other versions
DK168823B1 (en
DK619186A (en
Inventor
Paul Habermann
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of DK619186D0 publication Critical patent/DK619186D0/en
Publication of DK619186A publication Critical patent/DK619186A/en
Application granted granted Critical
Publication of DK168823B1 publication Critical patent/DK168823B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Suitable as "ballast portion" for fusion proteins is a part of the amino-acid sequence of interleukin-2 (IL-2) which comprises considerably less than 100 amino acids. It is advantageous to start from a synthetic IL-2 gene which is divided by unique cleavage sites into six segments of which up to three can be linked in any desired sequence by the building block principle. Specific constructions allowing the solubility of the fusion protein to be varied are possible.
DK619186A 1985-12-21 1986-12-19 Fusion proteins, wherein the ballast fraction consists of peptides of interleukin 2, method for their preparation, their use, gene structure encoding such a fusion protein, vector containing such a gene structure, and E. coli cell containing such vector. DK168823B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3545565 1985-12-21
DE3545565 1985-12-21
DE19863636903 DE3636903A1 (en) 1985-12-21 1986-10-30 FUSION PROTEINS WITH EUKARYOTIC BALLASTES
DE3636903 1986-10-30

Publications (3)

Publication Number Publication Date
DK619186D0 true DK619186D0 (en) 1986-12-19
DK619186A DK619186A (en) 1987-06-22
DK168823B1 DK168823B1 (en) 1994-06-20

Family

ID=25839208

Family Applications (1)

Application Number Title Priority Date Filing Date
DK619186A DK168823B1 (en) 1985-12-21 1986-12-19 Fusion proteins, wherein the ballast fraction consists of peptides of interleukin 2, method for their preparation, their use, gene structure encoding such a fusion protein, vector containing such a gene structure, and E. coli cell containing such vector.

Country Status (16)

Country Link
EP (1) EP0229998B1 (en)
JP (2) JP2553058B2 (en)
KR (1) KR950000301B1 (en)
AT (1) ATE78296T1 (en)
AU (1) AU599943B2 (en)
CA (1) CA1339894C (en)
DE (1) DE3636903A1 (en)
DK (1) DK168823B1 (en)
ES (1) ES2033678T3 (en)
FI (1) FI93734C (en)
GR (1) GR3005985T3 (en)
HU (1) HU209747B (en)
IE (1) IE58935B1 (en)
IL (1) IL81018A (en)
NO (1) NO175003C (en)
PT (1) PT83973B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3545568A1 (en) * 1985-12-21 1987-07-16 Hoechst Ag GM-CSF-PROTEIN, ITS DERIVATIVES, PRODUCTION OF SUCH PROTEINS AND THEIR USE
DE3844211A1 (en) * 1988-12-29 1990-07-05 Hoechst Ag NEW INSULINE DERIVATIVES, THE PROCESS FOR THEIR PRODUCTION, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
FR2643646B1 (en) * 1989-02-27 1993-09-17 Pasteur Institut EXPRESSION OF NUCLEOTIDES SEQUENCES ENCODING FOR GAS VESICLES
CU22222A1 (en) * 1989-08-03 1995-01-31 Cigb PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
DE3942580A1 (en) * 1989-12-22 1991-06-27 Basf Ag METHOD FOR PRODUCING HIRUDINE
DE4105480A1 (en) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh IMPROVED ACTIVATION OF RECOMBINANT PROTEINS
ATE264871T1 (en) 1996-07-26 2004-05-15 Aventis Pharma Gmbh INSULIN DERIVATIVES WITH INCREASED ZINC BINDING
DE19825447A1 (en) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh New insulin analogues with increased zinc formation
DE102006031962A1 (en) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidated insulin glargine
DE102006031955A1 (en) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Process for the preparation of dibasic B chain end insulin analogs
HUE037449T2 (en) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Combination of an insulin and a glp-1 agonist
EP3831402A1 (en) 2009-11-13 2021-06-09 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
ES2965209T3 (en) 2009-11-13 2024-04-11 Sanofi Aventis Deutschland Pharmaceutical composition comprising desPro36exendin-4(1-39)-Lys6-NH2 and methionine
PT2611458T (en) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (en) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland PHARMACEUTICAL COMBINATION FOR USE IN GLUCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
DK3229828T5 (en) 2014-12-12 2024-10-14 Sanofi Aventis Deutschland FORMULATION WITH FIXED RATIO BETWEEN INSULIN GLARGINE AND LIXISENATIDE
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
KR20200080748A (en) 2018-12-27 2020-07-07 주식회사 폴루스 A Method for Purifying Proinsulin Using Anion Exchange Chromatography
KR20200080747A (en) 2018-12-27 2020-07-07 주식회사 폴루스 An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK108685A (en) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co GROWTH FACTOR I
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
GB8412517D0 (en) * 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins

Also Published As

Publication number Publication date
EP0229998A3 (en) 1988-08-03
PT83973B (en) 1989-07-31
ES2033678T3 (en) 1993-04-01
PT83973A (en) 1987-01-01
KR950000301B1 (en) 1995-01-13
JPS62167799A (en) 1987-07-24
NO175003C (en) 1994-08-17
JP2774260B2 (en) 1998-07-09
IE863334L (en) 1987-06-21
CA1339894C (en) 1998-06-02
KR870006187A (en) 1987-07-09
EP0229998A2 (en) 1987-07-29
FI865187A0 (en) 1986-12-18
DK168823B1 (en) 1994-06-20
FI865187A (en) 1987-06-22
DE3636903A1 (en) 1987-07-02
JPH08187089A (en) 1996-07-23
ATE78296T1 (en) 1992-08-15
JP2553058B2 (en) 1996-11-13
NO865192D0 (en) 1986-12-19
AU6676086A (en) 1987-06-25
AU599943B2 (en) 1990-08-02
FI93734C (en) 1995-05-26
HUT44614A (en) 1988-03-28
HU209747B (en) 1994-10-28
NO865192L (en) 1987-06-22
NO175003B (en) 1994-05-09
IL81018A0 (en) 1987-03-31
GR3005985T3 (en) 1993-06-07
IL81018A (en) 1992-03-29
FI93734B (en) 1995-02-15
IE58935B1 (en) 1993-12-01
EP0229998B1 (en) 1992-07-15
DK619186A (en) 1987-06-22

Similar Documents

Publication Publication Date Title
DK619186A (en) FUSION PROTEINS WITH EUKARYOTIC BALL STANDARD
DK371087A (en) MAMALIALT INTERLEUKIN-4
FI863041A (en) FUSIONSPROTEIN, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING.
DE3873397D1 (en) BIFUNCTIONAL PROTEINS.
IT8647912A0 (en) ENZYMATIC PROCEDURE TO PREPARE SULFUR-CONTAINING AMINO ACIDS

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired